LVV- and VV-hemorphins: comparative levels in rat tissues  by Yatskin, Oleg N et al.
LVV- and VV-hemorphins: comparative levels in rat tissues
Oleg N. Yatskin*, Marina M. Philippova, Elena Yu. Blishchenko, Andrei A. Karelin,
Vadim T. Ivanov
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry Russian Academy of Sciences, ul. Miklukho-Maklaya 16/10, 117871 Moscow V-437, Russia
Received 24 February 1998
Abstract Screening of hemorphins in extracts of rat lung,
brain, heart and spleen was carried out. The threshold for
detection of hemorphins was 0.01 nmol for spleen and 0.05 nmol
for other tissues. Both the content and the composition of
hemorphins differed significantly in the tissues analyzed. Heart
and lung extracts were rich in these peptides, the content of the
most abundant components reaching 16^44 nmol/g of tissue. In
contrast, spleen and brain contained much lower amounts of
hemorphins, i.e. about 0.3^2.6 nmol/g of tissue. The most
represented hemorphin in lung, heart and brain was VV-
hemorphin-5, while the content of other members of the
hemorphin family depended significantly on the tissue analyzed:
lung extract was also rich in LVV-hemorphin-5, heart contained
similar amounts of LVV-hemorphin-7 and LVV-hemorphin-5
and brain of LVV-hemorphin-6. In contrast, the hemorphin
family in spleen was represented mainly by C-terminally
shortened VV-hemorphins, i.e. VV-hemorphin-4 and VV-hemor-
phin-3. The levels of hemorphins in all cases were sufficient to
activate the opioid receptors of the respective tissues.
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1. Introduction
In 1986 Brantl et al. found that proteolytic treatment of
hemoglobin in vitro gives rise to peptides, called hemorphin-
4 (L-globin 35^38) and hemorphin-5 (L-globin 35^39) and
endowed with opioid-like activity [1,2]. Endogenous hemor-
phin-related peptides were isolated from brain [3^7], blood
plasma [8], cerebrospinal £uid [9], spinal cord [10] and the
supernatants of primary cultures of red bone marrow cells
[11] and erythrocytes [12]. The members of that family of
peptides are generated by proteolytic degradation of the
(32^41) segment of the L-chain of hemoglobin. Being active
in three basic opioid tests : inhibition of opioid ligand binding
to brain membranes [4,5,13^15], induction of naloxone-de-
pendent analgesia in rats in vivo [2,16] and contractile activity
at the guinea pig ileum (GPI) [1,4,5,13,15], hemorphins are
considered non-classical opioid peptides. Other e¡ects related
to the opioid nature of hemorphins are also re£ected in the
literature, such as coronaro-constrictory [17], antitumor [18]
and immunoregulatory activities [19], as well as inhibition of
angiotensin-converting enzyme [15,20,21]. At the same time,
the binding a⁄nities of hemorphins to opioid receptors are
much lower than those of classical opioid peptides. However,
we suggested that the overall e¡ect of hemorphins on the
opioid receptor system could be comparable with the action
of classical opiates, enkephalins and endorphins, due to the
relatively high content of these hemoglobin fragments in the
tissue [7,23]. In order to obtain quantitative data related to
that concept we measured in this work the levels of hemor-
phins in rat lung, heart, brain and spleen.
2. Materials and methods
2.1. Preparation of rat tissue extracts
Rat tissues were stored in liquid nitrogen. 4^6 g of brain, lung,
heart and spleen tissues were homogenized in a Potter homogenizer
in 20^30 ml of 10% acetic acid. The obtained mixture was centrifuged
at 1500Ug for 15 min. All procedures were carried out within 17^18
min at 4‡C. Supernatants were lyophilized.
2.2. Peptide synthesis
LVV-hemorphin-7, LVV-hemorphin-5 and VV-hemorphin-5 were
synthesized on solid phase using the Boc technique in the Laboratory
of Peptide Chemistry of our institute and characterized by nuclear
magnetic resonance and mass spectrometry analysis.
2.3. Size exclusion chromatography
The size exclusion fractionation was performed using the liquid
chromatography set (Pharmacia/LKB, Sweden) on a Sephadex G-
25sf column (2.5U85 cm) equilibrated with 0.1 M acetic acid. The
mixture of standard samples (1 mg of LVV-hemorphin-7; 2 mg of
LVV-hemorphin-5; 0.5 mg of VV-hemorphin-5) or 200 mg of the
lyophilized preparation of each tissue were dissolved in 12 ml of 0.1
M acetic acid and subjected to separation in conditions described in
the legend to Fig. 1. The obtained fractions were lyophilized.
2.4. Reverse phase HPLC
The fractions obtained after size exclusion chromatography and the
peptide standards were separated on a Nucleosil C8 120/5W (4.0U250
mm) cartridge equilibrated in bu¡er A (0.1% TFA in water). The
elution was performed with a linear gradient of acetonitrile from
0 to 60% of bu¡er B (0.1% TFA, 80% acetonitrile in water) for
60 min at 0.75 ml/min.
The collected fractions were rechromatographed on a Nucleosil C8
120/5W (4.0U250 mm) cartridge equilibrated in 0.05 M ammonium-
acetate bu¡er (pH 4.5). The elution was performed with a linear
gradient of acetonitrile from 30 to 50% of bu¡er C (0.05 M ammo-
nium-acetate bu¡er (pH 4.5), 80% acetonitrile in water) for 20 min at
0.75 ml/min. The elution pro¢les were recorded using the digitizer
(Ampersend, Russia) at 226 nm. The absorbance values for Figs. 2
and 3 correspond to the ratio 1800 mV = 2.56 AUFS. Analysis of the
elution pro¢les was performed using the MultiChrom-Spectr program,
version 2.67 (Ampersend, Russia).
Elution zones corresponding to hemorphin standards were exam-
ined by UV spectrum analysis at wavelengths 273 nm and 288 nm
using a multichannel photoarray detector (model 991, Waters). The
peaks with a Tyr/Trp absorbance ratio characteristic for hemorphins
(2:1) were identi¢ed as described in [22].
The content of hemorphins was calculated from sequencing data,
using the peak area normalization method by means of the Multi-
Chrom-Spectr program (version 2.67) and supported by UV spectrum
analysis.
Reproducibility of the data presented in this paper was ensured by
matching the elution pro¢les in ¢ve independent experiments. In sev-
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eral cases sequence analysis was used to verify the reproducibility of
the results.
The monitoring of the losses of peptide material was carried out
using the hemorphin standards at each separation stage. The total
losses of hemorphins were less than 5%.
2.5. Peptide sequencing and sequence identi¢cation
Amino acid sequences were determined by means of a gas phase
sequencer (Model 477A, Applied Biosystems). Identi¢cation of the
established sequences was performed using PIR data bank version 38.
3. Results
Rat tissues were treated using a standard procedure under
conditions ensuring minimal loss of original peptides [24,25].
The lyophilisates were fractionated on the Sephadex G-25sf
column and the fractions corresponding to the elution zone of
standard hemorphin mixtures (see below) were collected and
lyophilized (Fig. 1). The yields of the material in the fractions
obtained by separation of lung, heart, brain and spleen ex-
tracts were, respectively, 22.6, 14.6, 22.7, and 65.3 mg/g of
tissue.
The conditions for size exclusion fractionation were selected
using the mixture of synthetic preparations of LVV-hemor-
phin-7, LVV-hemorphin-5 and VV-hemorphin-5. Using these
standards the elution zone of hemorphins was determined
(Fig. 1). Based on the results of screening bovine brain ex-
tract, we expected the above mentioned tissues to contain, at
least, LVV-hemorphin-7, LVV-hemorphin-5, LVV-hemor-
phin-4, VV-hemorphin-7 and VV-hemorphin-5 [7,24]. The
chromatographic procedure developed for isolation of these
hemorphins was applied for analysis of rat brain extract (Figs.
1A and 2A). The peaks of components corresponding to the
zone of elution of hemorphins were subjected to three-dimen-
sional spectral analysis and the peaks with a 2:1 Tyr/Trp
absorbance ratio were isolated and sequenced. Because of
poor resolution of the substances corresponding to the shaded
peaks in elution bu¡er containing 0.1% TFA, an additional
puri¢cation stage was required. The non-resolved peaks were
rechromatographed using 0.05 M ammonium-acetate bu¡er
(pH 4.5) in conditions given in the legend to Fig. 2. As seen
from Fig. 3, a resolution su⁄cient for sequencing analysis was
achieved. As a result, the amino acid sequences of 10 hemor-
phins were established (Table 1). The chromatographic proce-
dure developed was applied for identifying and quantifying
hemorphins in rat lung, heart and spleen extracts. The frac-
tions obtained after size exclusion chromatography (Fig. 1B^
D) were subjected to further separation on Nucleosil C8 120/
5W (Fig. 2B^D) and the peaks with a 2:1 Tyr/Trp absorbance
ratio were isolated as described above and sequenced.
The data on composition and content of hemorphins in rat
tissues are summarized in Table 1. Ten hemorphins were
found in the rat brain, lung and heart and four in the spleen.
Additionally, three fragments of functional proteins with a
Tyr/Trp ratio similar to that of hemorphins were identi¢ed:
the fragment (309^322) of glyceraldehyde phosphate dehy-
drogenase (ISWYDNEYGYSNRV) was isolated from the
brain extract (Fig. 2A, peak I) [24] ; the fragment (12^25)
of the K-chain of hemoglobin (NCWGKIGGHGGEYGE)
and the fragment (13^23) of carbonate dehydratase I
(GPDNWSKLYPI) (Fig. 2D, peaks II and III, respectively)
were isolated from spleen.
As seen from Table 1, both the content and the composi-
tion of hemorphins di¡er signi¢cantly in the tissues analyzed.
Heart and lung extracts were rich in hemorphins, the contents
of the most abundant components being, respectively, 16 and
44 nmol/g of tissue. In contrast, spleen and brain contained
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Fig. 1. Size exclusion chromatography of rat tissue extracts on a Sephadex G-25sf (2.5U85 cm) column equilibrated with 0.1 M acetic acid.
The collected fractions are marked. Elution pro¢le of standard mixture of hemorphins is shown. A: brain; B: heart; C: lung; D: spleen.
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much lower amounts of hemorphins, the total amounts of all
studied components being, respectively, only 0.35 and 2.6
nmol (per g of tissue). The peptide represented maximally in
lung, heart and brain was valorphin (VV-hemorphin-5), while
the content of other members of the hemorphin family de-
pended signi¢cantly on the tissue analyzed: lung extract was
also rich in LVV-hemorphin-5 (85% of the valorphin level),
heart contained similar amounts of LVV-hemorphin-7 and
LVV-hemorphin-5 (69% of the valorphin level) and brain of
LVV-hemorphin-6 (73% of the valorphin level). In contrast,
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Fig. 2. RP-HPLC of peptide fractions isolated from rat tissue extracts (Fig. 1) on a Nucleosil C8 120/5W (4.0U250 mm) cartridge equilibrated
with bu¡er A (0.1% TFA in water) in a linear gradient of acetonitrile. Shading marks the elution zone of hemorphins. A: brain; B: heart;
C: lung; D: spleen. Insertions show the fragments of elution zones of hemorphins. The numbers correspond to peptides represented in Table 1.
Fig. 3. Reverse phase rechromatography of hemorhins on a Nucleosil C8 120/5W (4.0U250 mm) cartridge in a linear gradient of acetonitrile.
A: Fragment of the elution pro¢le obtained after separation of the prepared mixture of hemorphins isolated from rat tissues. The column was
equilibrated with 0.1% TFA. Shading marks the elution zones of non-resolved hemorphins. B^D: Rechromatography of non-resolved hemor-
phins on the column equilibrated with 0.05 M ammonium-acetate bu¡er (pH 4.5) (substances 4, 5; 2, 6; and 9, 10, respectively). The numbers
correspond to peptides represented in Table 1.
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the hemorphin family in spleen was represented mainly by C-
terminally shortened VV-hemorphins, i.e. VV-hemorphin-4
and VV-hemorphin-3, their contents were, respectively, 17-
and 12-fold higher than that of valorphin.
4. Discussion
The data presented in Table 1 show that LVV-hemorphin-7,
LVV-hemorphin-5 and VV-hemorphin-5 (valorphin) are
present in lung and heart tissues in amounts su⁄cient for
manifestation of their opioid activity, which requires 10^100
WM of these peptides [4,5,13^15]. The levels of LVV-hemor-
phin-6, LVV-hemorphin-4 and VV-hemorphin-6 in lung also
corresponded to their binding a⁄nity to opioid receptors. We
suggested earlier that the classical regulatory peptide and the
fragment of a functional protein might act at the same recep-
tor and the hormone-induced signal can be controlled by the
level of proteolytic activity in the tissue. In this case, the high
content of hemorphins might compensate for the relatively
low binding parameters of these peptides. For example, the
binding constants of hemorphins maximally presented in tis-
sue extracts with W-opioid receptors are higher by several or-
ders of magnitude than for Leu-enkephalin, (respectively, 1^
50 WM [22] and 0.03^0.04 WM [4]). However, the overall con-
tent of hemorphins in lung, heart and brain tissues, as seen
from Table 1, is approximately, 3^70 nmol/g compared to
0.02^0.2 nmol/g in the case of Leu-enkephalin in brain [26].
Since members of the hemorphin family have been shown to
induce cytotoxicity and to decrease proliferation of tumor
cells at very low concentrations (1036^10313 M) [18], as com-
pared with the concentrations needed for manifesting the
opioid e¡ects, the content of less abundant hemorphins in
tissues might be quite su⁄cient for inducing of cytotoxic
and antiproliferative e¡ects, characteristic for ‘classical’ li-
gands of opioid receptors [27] or the opioid-like peptides ca-
somorphins [28].
The data obtained allow us to compare the composition of
hemorphins in the examined tissues with that of biological
£uids. In contrast to tissues, human blood plasma and cere-
brospinal £uid were shown to contain very low amounts of
hemorphins (respectively, less than 2.0 pmol/ml [8] and less
than 3.5 pmol/ml [9]). The content of hemorphin-7 increases
3^4-fold in human blood plasma after marathon running [8]
and LVV-hemorphin-7 increases in cerebrospinal £uid up to
115^300 pmol/ml during cerebrovascular bleeding [9]. The lev-
el of that peptide was also shown to rise in the plasma of
patients undergoing hemo¢ltration [29]. In other words,
changes of hemorphin content in biological £uids are associ-
ated with alterations in the organism state. Rough estimation
shows that the scale of these changes (up to 0.3 WM) might be
su⁄cient for induction of opioid-like e¡ects of hemorphins in
vivo.
Recently we found that human erythrocytes release a set of
hemorphin-related peptides di¡erent from that detected in tis-
sue extracts [12]. Supernatant of human erythrocytes con-
tained hemorphin-7, as well as V-hemorphin-7, V-hemor-
phin-5 and V-hemorphin-3, which have not been identi¢ed
earlier. At the same time, LVV- and VV-hemorphins were
not detected in the supernatant. These ¢ndings indicate that
there must be more than one mechanism of generation of
hemorphins in vivo, i.e. in addition to production by eryth-
rocytes, proteolytic enzymes of tissues should be involved in
formation of these peptides. For instance, macrophages were
shown to produce VV-hemorphin-7 from hemoglobin in vitro
[30].
Signi¢cant di¡erences in the patterns of hemorphins in dif-
ferent biological sources might be related to variations in the
spectra of their activity in vivo. In any case, we believe that
the e¡ects of hemorphins overlap with the functions of ‘clas-
sical’ opioid peptides: from in£uence on physiological proc-
esses in the tissues or the whole organism to regulation of the
activity of immune cells or elimination of tumor cells.
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